AstraZeneca PLC

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, LLY has a market cap of 607.1B. Regarding current trading prices, AZN is priced at $73.60, while LLY trades at $746.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas LLY's P/E ratio is 52.00. In terms of profitability, AZN's ROE is +0.20%, compared to LLY's ROE of +0.77%. Regarding short-term risk, AZN is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check LLY's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, JNJ has a market cap of 413.1B. Regarding current trading prices, AZN is priced at $73.60, while JNJ trades at $170.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas JNJ's P/E ratio is 18.34. In terms of profitability, AZN's ROE is +0.20%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, AZN is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for AZN.Check JNJ's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, ABBV has a market cap of 351.3B. Regarding current trading prices, AZN is priced at $73.60, while ABBV trades at $196.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas ABBV's P/E ratio is 94.70. In terms of profitability, AZN's ROE is +0.20%, compared to ABBV's ROE of +0.86%. Regarding short-term risk, AZN is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for AZN.Check ABBV's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, NVS has a market cap of 226.4B. Regarding current trading prices, AZN is priced at $73.60, while NVS trades at $113.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas NVS's P/E ratio is 16.91. In terms of profitability, AZN's ROE is +0.20%, compared to NVS's ROE of +0.23%. Regarding short-term risk, AZN is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for AZN.Check NVS's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, NVO has a market cap of 214.5B. Regarding current trading prices, AZN is priced at $73.60, while NVO trades at $45.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas NVO's P/E ratio is 12.60. In terms of profitability, AZN's ROE is +0.20%, compared to NVO's ROE of +0.81%. Regarding short-term risk, AZN is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check NVO's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, MRK has a market cap of 201.8B. Regarding current trading prices, AZN is priced at $73.60, while MRK trades at $79.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas MRK's P/E ratio is 12.39. In terms of profitability, AZN's ROE is +0.20%, compared to MRK's ROE of +0.38%. Regarding short-term risk, AZN is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check MRK's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, AMGN has a market cap of 153.1B. Regarding current trading prices, AZN is priced at $73.60, while AMGN trades at $284.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas AMGN's P/E ratio is 23.26. In terms of profitability, AZN's ROE is +0.20%, compared to AMGN's ROE of +0.98%. Regarding short-term risk, AZN is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check AMGN's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, PFE has a market cap of 137.9B. Regarding current trading prices, AZN is priced at $73.60, while PFE trades at $23.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas PFE's P/E ratio is 12.83. In terms of profitability, AZN's ROE is +0.20%, compared to PFE's ROE of +0.12%. Regarding short-term risk, AZN is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check PFE's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, GILD has a market cap of 137.2B. Regarding current trading prices, AZN is priced at $73.60, while GILD trades at $110.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas GILD's P/E ratio is 14.25. In terms of profitability, AZN's ROE is +0.20%, compared to GILD's ROE of +0.32%. Regarding short-term risk, AZN is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for AZN.Check GILD's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, SNY has a market cap of 115.7B. Regarding current trading prices, AZN is priced at $73.60, while SNY trades at $46.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas SNY's P/E ratio is 15.86. In terms of profitability, AZN's ROE is +0.20%, compared to SNY's ROE of +0.12%. Regarding short-term risk, AZN is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check SNY's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, BMY has a market cap of 92.3B. Regarding current trading prices, AZN is priced at $73.60, while BMY trades at $44.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas BMY's P/E ratio is 18.22. In terms of profitability, AZN's ROE is +0.20%, compared to BMY's ROE of +0.30%. Regarding short-term risk, AZN is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check BMY's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, CELG-RI has a market cap of 86.8B. Regarding current trading prices, AZN is priced at $73.60, while CELG-RI trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, AZN's ROE is +0.20%, compared to CELG-RI's ROE of +0.30%. Regarding short-term risk, AZN is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check CELG-RI's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, GSK has a market cap of 75.8B. Regarding current trading prices, AZN is priced at $73.60, while GSK trades at $36.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas GSK's P/E ratio is 17.09. In terms of profitability, AZN's ROE is +0.20%, compared to GSK's ROE of +0.24%. Regarding short-term risk, AZN is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for AZN.Check GSK's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, AZN is priced at $73.60, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AZN's ROE is +0.20%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AZN is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for AZN.Check HZNP's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, BIIB has a market cap of 18.7B. Regarding current trading prices, AZN is priced at $73.60, while BIIB trades at $129.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas BIIB's P/E ratio is 12.22. In terms of profitability, AZN's ROE is +0.20%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, AZN is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check BIIB's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, GRFS has a market cap of 9.2B. Regarding current trading prices, AZN is priced at $73.60, while GRFS trades at $10.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas GRFS's P/E ratio is 20.88. In terms of profitability, AZN's ROE is +0.20%, compared to GRFS's ROE of +0.05%. Regarding short-term risk, AZN is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check GRFS's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, OGN has a market cap of 2.4B. Regarding current trading prices, AZN is priced at $73.60, while OGN trades at $8.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas OGN's P/E ratio is 3.39. In terms of profitability, AZN's ROE is +0.20%, compared to OGN's ROE of +1.47%. Regarding short-term risk, AZN is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check OGN's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, CTOR has a market cap of 141.9M. Regarding current trading prices, AZN is priced at $73.60, while CTOR trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas CTOR's P/E ratio is -4.76. In terms of profitability, AZN's ROE is +0.20%, compared to CTOR's ROE of -0.34%. Regarding short-term risk, AZN is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check CTOR's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, SCLX has a market cap of 110.4M. Regarding current trading prices, AZN is priced at $73.60, while SCLX trades at $14.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas SCLX's P/E ratio is -1.04. In terms of profitability, AZN's ROE is +0.20%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, AZN is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check SCLX's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, SCLXW has a market cap of 97M. Regarding current trading prices, AZN is priced at $73.60, while SCLXW trades at $0.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas SCLXW's P/E ratio is N/A. In terms of profitability, AZN's ROE is +0.20%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, AZN is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check SCLXW's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, MIRA has a market cap of 23.8M. Regarding current trading prices, AZN is priced at $73.60, while MIRA trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas MIRA's P/E ratio is -2.91. In terms of profitability, AZN's ROE is +0.20%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, AZN is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check MIRA's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, SRXH has a market cap of 12M. Regarding current trading prices, AZN is priced at $73.60, while SRXH trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas SRXH's P/E ratio is N/A. In terms of profitability, AZN's ROE is +0.20%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, AZN is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check SRXH's competition here

AZN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZN stands at 231.2B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, AZN is priced at $73.60, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZN currently has a P/E ratio of 28.03, whereas CRXT's P/E ratio is -0.02. In terms of profitability, AZN's ROE is +0.20%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, AZN is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for AZN.Check CRXT's competition here